セリアック病治療薬市場は、2022年から2027年の間に7億159万米ドル成長すると予測されており、予測期間中にCAGRは17.01%で加速します。 セリアック病薬市場に関するレポートは、全体的な分析、市場規模と予測、傾向、成長ドライバー、課題、および約25のベンダーをカバーするベンダー分析を提供します。
	このレポートは、現在の市場シナリオ、最新の傾向と推進力、および全体的な市場環境に関する最新の分析を提供します。この市場は、グルテン含有食品の消費量の増加、セリアック病の蔓延、政府の取り組みによって牽引されています。
	この調査は、無機成長戦略が今後数年間のセリアック病治療薬市場の成長を促進する主な理由の1つであることを特定しています。また、セリアック病治療における有望な開発の増加、有病率と診断の増加により、市場での大きな需要がもたらされるでしょう。
	この調査は、業界の主要参加者からの意見を含む一次情報と二次情報を客観的に組み合わせて実施されました。このレポートには、主要ベンダーの分析に加えて、包括的な市場とベンダーの状況が含まれています。
	このレポートは、利益、価格設定、競争、プロモーションなどの主要なパラメーターの分析による複数のソースからのデータの調査、合成、合計により、市場の詳細な全体像を提示します。業界の主要な影響力を持つ企業を特定することで、さまざまな市場の側面を示します。提示されたデータは包括的で信頼性が高く、一次および二次の両方にわたる広範な研究の結果です。市場調査レポートは、正確な市場の成長を予測するための定性的および定量的調査を使用した、完全な競争状況と詳細なベンダー選択方法論および分析を提供します。
								
						目次
						
	Table of Contents
	1 Executive Summary
	
	1.1 Market overview
	Exhibit 01: Executive Summary - Chart on Market Overview
	Exhibit 02: Executive Summary - Data Table on Market Overview
	Exhibit 03: Executive Summary - Chart on Global Market Characteristics
	Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
	Exhibit 05: Executive Summary - Chart on Market Segmentation by Therapy
	Exhibit 06: Executive Summary - Chart on Market Segmentation by Route of Administration
	Exhibit 07: Executive Summary - Chart on Incremental Growth
	Exhibit 08: Executive Summary - Data Table on Incremental Growth
	Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
	2 Market Landscape
	
	2.1 Market ecosystem
	Exhibit 10: Parent market
	Exhibit 11: Market Characteristics
	3 Market Sizing
	
	3.1 Market definition
	Exhibit 12: Offerings of vendors included in the market definition
	3.2 Market segment analysis
	Exhibit 13: Market segments
	3.3 Market size 2022
	3.4 Market outlook: Forecast for 2022-2027
	Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
	Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
	Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
	Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
	4 Historic Market Size
	
	4.1 Global celiac diseases drugs market 2017 - 2021
	Exhibit 18: Historic Market Size - Data Table on global celiac diseases drugs market 2017 - 2021 ($ million)
	4.2 Therapy Segment Analysis 2017 - 2021
	Exhibit 19: Historic Market Size - Therapy Segment 2017 - 2021 ($ million)
	4.3 Route of Administration Segment Analysis 2017 - 2021
	Exhibit 20: Historic Market Size - Route of Administration Segment 2017 - 2021 ($ million)
	4.4 Geography Segment Analysis 2017 - 2021
	Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
	4.5 Country Segment Analysis 2017 - 2021
	Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
	5 Five Forces Analysis
	
	5.1 Five forces summary
	Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
	5.2 Bargaining power of buyers
	Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
	5.3 Bargaining power of suppliers
	Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
	5.4 Threat of new entrants
	Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
	5.5 Threat of substitutes
	Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
	5.6 Threat of rivalry
	Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
	5.7 Market condition
	Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
	6 Market Segmentation by Therapy
	
	6.1 Market segments
	Exhibit 30: Chart on Therapy - Market share 2022-2027 (%)
	Exhibit 31: Data Table on Therapy - Market share 2022-2027 (%)
	6.2 Comparison by Therapy
	Exhibit 32: Chart on Comparison by Therapy
	Exhibit 33: Data Table on Comparison by Therapy
	6.3 First line treatment - Market size and forecast 2022-2027
	Exhibit 34: Chart on First line treatment - Market size and forecast 2022-2027 ($ million)
	Exhibit 35: Data Table on First line treatment - Market size and forecast 2022-2027 ($ million)
	Exhibit 36: Chart on First line treatment - Year-over-year growth 2022-2027 (%)
	Exhibit 37: Data Table on First line treatment - Year-over-year growth 2022-2027 (%)
	6.4 Second-line treatment - Market size and forecast 2022-2027
	Exhibit 38: Chart on Second-line treatment - Market size and forecast 2022-2027 ($ million)
	Exhibit 39: Data Table on Second-line treatment - Market size and forecast 2022-2027 ($ million)
	Exhibit 40: Chart on Second-line treatment - Year-over-year growth 2022-2027 (%)
	Exhibit 41: Data Table on Second-line treatment - Year-over-year growth 2022-2027 (%)
	6.5 Market opportunity by Therapy
	Exhibit 42: Market opportunity by Therapy ($ million)
	Exhibit 43: Data Table on Market opportunity by Therapy ($ million)
	7 Market Segmentation by Route of Administration
	
	7.1 Market segments
	Exhibit 44: Chart on Route of Administration - Market share 2022-2027 (%)
	Exhibit 45: Data Table on Route of Administration - Market share 2022-2027 (%)
	7.2 Comparison by Route of Administration
	Exhibit 46: Chart on Comparison by Route of Administration
	Exhibit 47: Data Table on Comparison by Route of Administration
	7.3 Oral - Market size and forecast 2022-2027
	Exhibit 48: Chart on Oral - Market size and forecast 2022-2027 ($ million)
	Exhibit 49: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
	Exhibit 50: Chart on Oral - Year-over-year growth 2022-2027 (%)
	Exhibit 51: Data Table on Oral - Year-over-year growth 2022-2027 (%)
	7.4 Parenteral - Market size and forecast 2022-2027
	Exhibit 52: Chart on Parenteral - Market size and forecast 2022-2027 ($ million)
	Exhibit 53: Data Table on Parenteral - Market size and forecast 2022-2027 ($ million)
	Exhibit 54: Chart on Parenteral - Year-over-year growth 2022-2027 (%)
	Exhibit 55: Data Table on Parenteral - Year-over-year growth 2022-2027 (%)
	7.5 Market opportunity by Route of Administration
	Exhibit 56: Market opportunity by Route of Administration ($ million)
	Exhibit 57: Data Table on Market opportunity by Route of Administration ($ million)
	8 Customer Landscape
	
	8.1 Customer landscape overview
	Exhibit 58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
	9 Geographic Landscape
	
	9.1 Geographic segmentation
	Exhibit 59: Chart on Market share By Geographical Landscape 2022-2027 (%)
	Exhibit 60: Data Table on Market share By Geographical Landscape 2022-2027 (%)
	9.2 Geographic comparison
	Exhibit 61: Chart on Geographic comparison
	Exhibit 62: Data Table on Geographic comparison
	9.3 North America - Market size and forecast 2022-2027
	Exhibit 63: Chart on North America - Market size and forecast 2022-2027 ($ million)
	Exhibit 64: Data Table on North America - Market size and forecast 2022-2027 ($ million)
	Exhibit 65: Chart on North America - Year-over-year growth 2022-2027 (%)
	Exhibit 66: Data Table on North America - Year-over-year growth 2022-2027 (%)
	9.4 Europe - Market size and forecast 2022-2027
	Exhibit 67: Chart on Europe - Market size and forecast 2022-2027 ($ million)
	Exhibit 68: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
	Exhibit 69: Chart on Europe - Year-over-year growth 2022-2027 (%)
	Exhibit 70: Data Table on Europe - Year-over-year growth 2022-2027 (%)
	9.5 Asia - Market size and forecast 2022-2027
	Exhibit 71: Chart on Asia - Market size and forecast 2022-2027 ($ million)
	Exhibit 72: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
	Exhibit 73: Chart on Asia - Year-over-year growth 2022-2027 (%)
	Exhibit 74: Data Table on Asia - Year-over-year growth 2022-2027 (%)
	9.6 Rest of World (ROW) - Market size and forecast 2022-2027
	Exhibit 75: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
	Exhibit 76: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
	Exhibit 77: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
	Exhibit 78: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
	9.7 US - Market size and forecast 2022-2027
	Exhibit 79: Chart on US - Market size and forecast 2022-2027 ($ million)
	Exhibit 80: Data Table on US - Market size and forecast 2022-2027 ($ million)
	Exhibit 81: Chart on US - Year-over-year growth 2022-2027 (%)
	Exhibit 82: Data Table on US - Year-over-year growth 2022-2027 (%)
	9.8 Canada - Market size and forecast 2022-2027
	Exhibit 83: Chart on Canada - Market size and forecast 2022-2027 ($ million)
	Exhibit 84: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
	Exhibit 85: Chart on Canada - Year-over-year growth 2022-2027 (%)
	Exhibit 86: Data Table on Canada - Year-over-year growth 2022-2027 (%)
	9.9 Germany - Market size and forecast 2022-2027
	Exhibit 87: Chart on Germany - Market size and forecast 2022-2027 ($ million)
	Exhibit 88: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
	Exhibit 89: Chart on Germany - Year-over-year growth 2022-2027 (%)
	Exhibit 90: Data Table on Germany - Year-over-year growth 2022-2027 (%)
	9.10 UK - Market size and forecast 2022-2027
	Exhibit 91: Chart on UK - Market size and forecast 2022-2027 ($ million)
	Exhibit 92: Data Table on UK - Market size and forecast 2022-2027 ($ million)
	Exhibit 93: Chart on UK - Year-over-year growth 2022-2027 (%)
	Exhibit 94: Data Table on UK - Year-over-year growth 2022-2027 (%)
	9.11 China - Market size and forecast 2022-2027
	Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million)
	Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
	Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
	Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)
	9.12 Market opportunity By Geographical Landscape
	Exhibit 99: Market opportunity By Geographical Landscape ($ million)
	Exhibit 100: Data Tables on Market opportunity By Geographical Landscape ($ million)
	10 Drivers, Challenges, and Trends
	
	10.1 Market drivers
	10.2 Market challenges
	10.3 Impact of drivers and challenges
	Exhibit 101: Impact of drivers and challenges in 2022 and 2027
	10.4 Market trends
	11 Vendor Landscape
	
	11.1 Overview
	11.2 Vendor landscape
	Exhibit 102: Overview on Criticality of inputs and Factors of differentiation
	11.3 Landscape disruption
	Exhibit 103: Overview on factors of disruption
	11.4 Industry risks
	Exhibit 104: Impact of key risks on business
	12 Vendor Analysis
	
	12.1 Vendors covered
	Exhibit 105: Vendors covered
	12.2 Market positioning of vendors
	Exhibit 106: Matrix on vendor position and classification
	12.3 Adaptive Biotechnologies Corp.
	Exhibit 107: Adaptive Biotechnologies Corp. - Overview
	Exhibit 108: Adaptive Biotechnologies Corp. - Product / Service
	Exhibit 109: Adaptive Biotechnologies Corp. - Key offerings
	12.4 Almirall SA
	Exhibit 110: Almirall SA - Overview
	Exhibit 111: Almirall SA - Product / Service
	Exhibit 112: Almirall SA - Key news
	Exhibit 113: Almirall SA - Key offerings
	12.5 Amgen Inc.
	Exhibit 114: Amgen Inc. - Overview
	Exhibit 115: Amgen Inc. - Product / Service
	Exhibit 116: Amgen Inc. - Key offerings
	12.6 AMYRA Biotech AG
	Exhibit 117: AMYRA Biotech AG - Overview
	Exhibit 118: AMYRA Biotech AG - Product / Service
	Exhibit 119: AMYRA Biotech AG - Key offerings
	12.7 BioLineRx Ltd.
	Exhibit 120: BioLineRx Ltd. - Overview
	Exhibit 121: BioLineRx Ltd. - Product / Service
	Exhibit 122: BioLineRx Ltd. - Key offerings
	12.8 Bristol Myers Squibb Co.
	Exhibit 123: Bristol Myers Squibb Co. - Overview
	Exhibit 124: Bristol Myers Squibb Co. - Product / Service
	Exhibit 125: Bristol Myers Squibb Co. - Key news
	Exhibit 126: Bristol Myers Squibb Co. - Key offerings
	12.9 Calypso Biotech BV
	Exhibit 127: Calypso Biotech BV - Overview
	Exhibit 128: Calypso Biotech BV - Product / Service
	Exhibit 129: Calypso Biotech BV - Key offerings
	12.10 GlaxoSmithKline Plc
	Exhibit 130: GlaxoSmithKline Plc - Overview
	Exhibit 131: GlaxoSmithKline Plc - Business segments
	Exhibit 132: GlaxoSmithKline Plc - Key news
	Exhibit 133: GlaxoSmithKline Plc - Key offerings
	Exhibit 134: GlaxoSmithKline Plc - Segment focus
	12.11 Glenmark Pharmaceuticals Ltd.
	Exhibit 135: Glenmark Pharmaceuticals Ltd. - Overview
	Exhibit 136: Glenmark Pharmaceuticals Ltd. - Product / Service
	Exhibit 137: Glenmark Pharmaceuticals Ltd. - Key offerings
	12.12 ImmunogenX Inc.
	Exhibit 138: ImmunogenX Inc. - Overview
	Exhibit 139: ImmunogenX Inc. - Product / Service
	Exhibit 140: ImmunogenX Inc. - Key offerings
	12.13 Johnson and Johnson
	Exhibit 141: Johnson and Johnson - Overview
	Exhibit 142: Johnson and Johnson - Business segments
	Exhibit 143: Johnson and Johnson - Key news
	Exhibit 144: Johnson and Johnson - Key offerings
	Exhibit 145: Johnson and Johnson - Segment focus
	12.14 Precigen Inc.
	Exhibit 146: Precigen Inc. - Overview
	Exhibit 147: Precigen Inc. - Business segments
	Exhibit 148: Precigen Inc. - Key offerings
	Exhibit 149: Precigen Inc. - Segment focus
	12.15 Sanofi
	Exhibit 150: Sanofi - Overview
	Exhibit 151: Sanofi - Business segments
	Exhibit 152: Sanofi - Key news
	Exhibit 153: Sanofi - Key offerings
	Exhibit 154: Sanofi - Segment focus
	12.16 Takeda Pharmaceutical Co. Ltd.
	Exhibit 155: Takeda Pharmaceutical Co. Ltd. - Overview
	Exhibit 156: Takeda Pharmaceutical Co. Ltd. - Product / Service
	Exhibit 157: Takeda Pharmaceutical Co. Ltd. - Key news
	Exhibit 158: Takeda Pharmaceutical Co. Ltd. - Key offerings
	12.17 Teva Pharmaceutical Industries Ltd.
	Exhibit 159: Teva Pharmaceutical Industries Ltd. - Overview
	Exhibit 160: Teva Pharmaceutical Industries Ltd. - Business segments
	Exhibit 161: Teva Pharmaceutical Industries Ltd. - Key news
	Exhibit 162: Teva Pharmaceutical Industries Ltd. - Key offerings
	Exhibit 163: Teva Pharmaceutical Industries Ltd. - Segment focus
	13 Appendix
	
	13.1 Scope of the report
	13.2 Inclusions and exclusions checklist
	Exhibit 164: Inclusions checklist
	Exhibit 165: Exclusions checklist
	13.3 Currency conversion rates for US$
	Exhibit 166: Currency conversion rates for US$
	13.4 Research methodology
	Exhibit 167: Research methodology
	Exhibit 168: Validation techniques employed for market sizing
	Exhibit 169: Information sources
	13.5 List of abbreviations
	Exhibit 170: List of abbreviations
Exhibits:
Exhibits1: Executive Summary - Chart on Market Overview
Exhibits2: Executive Summary - Data Table on Market Overview
Exhibits3: Executive Summary - Chart on Global Market Characteristics
Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits5: Executive Summary - Chart on Market Segmentation by Therapy
Exhibits6: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibits7: Executive Summary - Chart on Incremental Growth
Exhibits8: Executive Summary - Data Table on Incremental Growth
Exhibits9: Executive Summary - Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size - Data Table on global celiac diseases drugs market 2017 - 2021 ($ million)
Exhibits19: Historic Market Size - Therapy Segment 2017 - 2021 ($ million)
Exhibits20: Historic Market Size - Route of Administration Segment 2017 - 2021 ($ million)
Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
Exhibits23: Five forces analysis - Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition - Five forces 2022 and 2027
Exhibits30: Chart on Therapy - Market share 2022-2027 (%)
Exhibits31: Data Table on Therapy - Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Therapy
Exhibits33: Data Table on Comparison by Therapy
Exhibits34: Chart on First line treatment - Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on First line treatment - Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on First line treatment - Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on First line treatment - Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Second-line treatment - Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Second-line treatment - Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Second-line treatment - Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Second-line treatment - Year-over-year growth 2022-2027 (%)
Exhibits42: Market opportunity by Therapy ($ million)
Exhibits43: Data Table on Market opportunity by Therapy ($ million)
Exhibits44: Chart on Route of Administration - Market share 2022-2027 (%)
Exhibits45: Data Table on Route of Administration - Market share 2022-2027 (%)
Exhibits46: Chart on Comparison by Route of Administration
Exhibits47: Data Table on Comparison by Route of Administration
Exhibits48: Chart on Oral - Market size and forecast 2022-2027 ($ million)
Exhibits49: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
Exhibits50: Chart on Oral - Year-over-year growth 2022-2027 (%)
Exhibits51: Data Table on Oral - Year-over-year growth 2022-2027 (%)
Exhibits52: Chart on Parenteral - Market size and forecast 2022-2027 ($ million)
Exhibits53: Data Table on Parenteral - Market size and forecast 2022-2027 ($ million)
Exhibits54: Chart on Parenteral - Year-over-year growth 2022-2027 (%)
Exhibits55: Data Table on Parenteral - Year-over-year growth 2022-2027 (%)
Exhibits56: Market opportunity by Route of Administration ($ million)
Exhibits57: Data Table on Market opportunity by Route of Administration ($ million)
Exhibits58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits59: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits60: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits61: Chart on Geographic comparison
Exhibits62: Data Table on Geographic comparison
Exhibits63: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibits64: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibits65: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibits66: Data Table on North America - Year-over-year growth 2022-2027 (%)
Exhibits67: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits68: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits69: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibits70: Data Table on Europe - Year-over-year growth 2022-2027 (%)
Exhibits71: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits72: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits73: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibits74: Data Table on Asia - Year-over-year growth 2022-2027 (%)
Exhibits75: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits76: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits77: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits78: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits79: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibits80: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibits81: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibits82: Data Table on US - Year-over-year growth 2022-2027 (%)
Exhibits83: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibits84: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibits85: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibits86: Data Table on Canada - Year-over-year growth 2022-2027 (%)
Exhibits87: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits88: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits89: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibits90: Data Table on Germany - Year-over-year growth 2022-2027 (%)
Exhibits91: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibits92: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibits93: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibits94: Data Table on UK - Year-over-year growth 2022-2027 (%)
Exhibits95: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibits96: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibits97: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibits98: Data Table on China - Year-over-year growth 2022-2027 (%)
Exhibits99: Market opportunity By Geographical Landscape ($ million)
Exhibits100: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits101: Impact of drivers and challenges in 2022 and 2027
Exhibits102: Overview on Criticality of inputs and Factors of differentiation
Exhibits103: Overview on factors of disruption
Exhibits104: Impact of key risks on business
Exhibits105: Vendors covered
Exhibits106: Matrix on vendor position and classification
Exhibits107: Adaptive Biotechnologies Corp. - Overview
Exhibits108: Adaptive Biotechnologies Corp. - Product / Service
Exhibits109: Adaptive Biotechnologies Corp. - Key offerings
Exhibits110: Almirall SA - Overview
Exhibits111: Almirall SA - Product / Service
Exhibits112: Almirall SA - Key news
Exhibits113: Almirall SA - Key offerings
Exhibits114: Amgen Inc. - Overview
Exhibits115: Amgen Inc. - Product / Service
Exhibits116: Amgen Inc. - Key offerings
Exhibits117: AMYRA Biotech AG - Overview
Exhibits118: AMYRA Biotech AG - Product / Service
Exhibits119: AMYRA Biotech AG - Key offerings
Exhibits120: BioLineRx Ltd. - Overview
Exhibits121: BioLineRx Ltd. - Product / Service
Exhibits122: BioLineRx Ltd. - Key offerings
Exhibits123: Bristol Myers Squibb Co. - Overview
Exhibits124: Bristol Myers Squibb Co. - Product / Service
Exhibits125: Bristol Myers Squibb Co. - Key news
Exhibits126: Bristol Myers Squibb Co. - Key offerings
Exhibits127: Calypso Biotech BV - Overview
Exhibits128: Calypso Biotech BV - Product / Service
Exhibits129: Calypso Biotech BV - Key offerings
Exhibits130: GlaxoSmithKline Plc - Overview
Exhibits131: GlaxoSmithKline Plc - Business segments
Exhibits132: GlaxoSmithKline Plc - Key news
Exhibits133: GlaxoSmithKline Plc - Key offerings
Exhibits134: GlaxoSmithKline Plc - Segment focus
Exhibits135: Glenmark Pharmaceuticals Ltd. - Overview
Exhibits136: Glenmark Pharmaceuticals Ltd. - Product / Service
Exhibits137: Glenmark Pharmaceuticals Ltd. - Key offerings
Exhibits138: ImmunogenX Inc. - Overview
Exhibits139: ImmunogenX Inc. - Product / Service
Exhibits140: ImmunogenX Inc. - Key offerings
Exhibits141: Johnson and Johnson - Overview
Exhibits142: Johnson and Johnson - Business segments
Exhibits143: Johnson and Johnson - Key news
Exhibits144: Johnson and Johnson - Key offerings
Exhibits145: Johnson and Johnson - Segment focus
Exhibits146: Precigen Inc. - Overview
Exhibits147: Precigen Inc. - Business segments
Exhibits148: Precigen Inc. - Key offerings
Exhibits149: Precigen Inc. - Segment focus
Exhibits150: Sanofi - Overview
Exhibits151: Sanofi - Business segments
Exhibits152: Sanofi - Key news
Exhibits153: Sanofi - Key offerings
Exhibits154: Sanofi - Segment focus
Exhibits155: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibits156: Takeda Pharmaceutical Co. Ltd. - Product / Service
Exhibits157: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibits158: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibits159: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits160: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits161: Teva Pharmaceutical Industries Ltd. - Key news
Exhibits162: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits163: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits164: Inclusions checklist
Exhibits165: Exclusions checklist
Exhibits166: Currency conversion rates for US$
Exhibits167: Research methodology
Exhibits168: Validation techniques employed for market sizing
Exhibits169: Information sources
Exhibits170: List of abbreviations